Pharmaron Unveils 2026 H Share Incentive Plan and Governance Overhaul
I'm LongbridgeAI, I can summarize articles.Pharmaron Beijing Co., Ltd. (HK:3759) announced a new 2026 H Share Incentive Plan, authorizing up to 28 million shares to boost employee motivation and long-term growth. The board also approved amendments to its articles of association to align with updated Chinese regulatory guidelines, enhancing corporate governance. These changes require shareholder approval. Analysts maintain a 'Buy' rating with a HK$28.10 price target.
An announcement from Pharmaron Beijing Co., Ltd. Class H ( (HK:3759) ) is now available.
Pharmaron Beijing Co., Ltd. plans to adopt a new 2026 H Share award and trust scheme, authorizing up to 28 million H shares sourced from repurchased treasury stock and potential new issuances. The 10-year scheme is designed to strengthen its equity incentive framework, bolster employee motivation and core team cohesion, and enhance the company’s competitiveness and long-term growth prospects in compliance with Hong Kong listing rules.
The board also approved proposed amendments to the company’s articles of association to align with updated Chinese and Shenzhen ChiNext regulatory guidelines. These changes aim to standardize wording, clarify rules on guarantees, connected transactions and actual controllers, and remove obsolete provisions, with final approval subject to shareholder resolutions and relevant regulatory authorities, reinforcing corporate governance and regulatory compliance.
The most recent analyst rating on (HK:3759) stock is a Buy
with a HK$28.10 price target.
To see the full list of analyst forecasts on Pharmaron Beijing Co., Ltd. Class H stock,
see the HK:3759 Stock Forecast page.
More about Pharmaron Beijing Co., Ltd. Class H
Pharmaron Beijing Co., Ltd. is a China-based contract research and development organization serving the pharmaceutical and biotech industries. The company focuses on providing integrated R&D and manufacturing services, including chemistry, biology and drug development support, to global healthcare clients and operates with H shares listed in Hong Kong and shares listed on the ChiNext Board in Shenzhen.
Average Trading Volume: 7,491,633
Technical Sentiment Signal: Buy
Current Market Cap: HK$75.07B